Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial.

@article{Aart2006IndividualizedDR,
  title={Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial.},
  author={Lonneke van Aart and Heleen W Eijkhout and Jan S Kamphuis and Marco Dam and Marinus Eeftinck Schattenkerk and Teunis J Schouten and Ben Ploeger and Paul F. W. Strengers},
  journal={Thrombosis research},
  year={2006},
  volume={118 3},
  pages={313-20}
}
Prothrombin Complex Concentrate (PCC) is indicated for the acute reversal of oral anticoagulation therapy. To compare the efficacy of a "standard" dosage of 20 ml PCC equivalent to about 500 IU factor IX (group A), and an "individualized" dosage based on a target-INR of 2.1 or 1.5, the initial-INR and the patient's body weight (group B), we performed an open, prospective, randomized, controlled trial. The in vivo response and in vivo recovery of factor II, VII, IX and X in these patients on… CONTINUE READING